- Home
- HSDT vs PHIO Comparison
HSDT vs PHIO Comparison
Compare HSDT & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- PHIO
- Stock Information
- Founded
- HSDT 2014
- PHIO 2011
- Country
- HSDT United States
- PHIO United States
- Employees
- HSDT N/A
- PHIO N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- HSDT Health Care
- PHIO Health Care
- Exchange
- HSDT Nasdaq
- PHIO Nasdaq
- Market Cap
- HSDT 2.5M
- PHIO 2.3M
- IPO Year
- HSDT N/A
- PHIO N/A
- Fundamental
- Price
- HSDT $0.49
- PHIO $2.61
- Analyst Decision
- HSDT Buy
- PHIO Strong Buy
- Analyst Count
- HSDT 2
- PHIO 1
- Target Price
- HSDT $24.00
- PHIO $36.00
- AVG Volume (30 Days)
- HSDT 236.6K
- PHIO 30.8K
- Earning Date
- HSDT 11-12-2024
- PHIO 11-14-2024
- Dividend Yield
- HSDT N/A
- PHIO N/A
- EPS Growth
- HSDT N/A
- PHIO N/A
- EPS
- HSDT N/A
- PHIO N/A
- Revenue
- HSDT $502,000.00
- PHIO N/A
- Revenue This Year
- HSDT N/A
- PHIO N/A
- Revenue Next Year
- HSDT $8.97
- PHIO N/A
- P/E Ratio
- HSDT N/A
- PHIO N/A
- Revenue Growth
- HSDT N/A
- PHIO N/A
- 52 Week Low
- HSDT $0.37
- PHIO $2.17
- 52 Week High
- HSDT $9.50
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- HSDT 44.03
- PHIO 48.74
- Support Level
- HSDT $0.43
- PHIO $2.58
- Resistance Level
- HSDT $0.76
- PHIO $2.91
- Average True Range (ATR)
- HSDT 0.08
- PHIO 0.21
- MACD
- HSDT -0.01
- PHIO 0.01
- Stochastic Oscillator
- HSDT 17.91
- PHIO 26.76
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.